Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease

Neurology

Volumn 49, Issue 3, 1997, Pages 711-713

  Verhagen Metman, L ^a   Van Den Munckhof, P ^a   Klaassen, A A G ^a   Blanchet, P ^a   Mouradian, M M ^a   Chase, Thomas N ^a,b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DYSKINESIA; EARLY DIAGNOSIS; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; STIMULUS RESPONSE;

EID: 0343580484     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.49.3.711     Document Type: Article

References (13)

1. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984;7:35-49.
2. Fabbrini G, Juncos J, Mouradian MM, Serrati C, Chase TN. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21:370-376.
3. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann Neurol 1988;24: 372-378.
4. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease: a clinical and neuropharmacological study. Brain 1984;107:487-506.
5. Mouradian MM, Heuser IJE, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989;25:523-526.
6. Nutt JG, Woodward WR. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 1986;36:739-744.
7. Davis TL, Brughitta G, Baronti F, Mouradian MM. Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics. Neurology 1991;41:630-633.
8. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990;40:340-345.
9. Fahn S. Is levodopa toxic? Neurology 1996;47(suppl 3):S184-S195.
10. Verhagen Metman L, Locatelli ER, Bravi D, Mouradian MM, Chase TN. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 1997;48: 369-372.
11. Papa SM, Boldry RC, Engber TN, Kask A, Chase TN. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 1995; 701:13-18.
12. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994; 36:27-31.
13. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv Neurol 1996;69:497-501.